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Abstract
pICln is a ubiquitous and abundant 27 kDa soluble protein that is localized primarily to the cytoplasm. The protein has
been proposed to be a swelling-activated anion channel or a channel regulator. Recent studies, however, have cast significant
doubt on these hypotheses, and the function of pICln therefore remains unknown. To further characterize the physiological
role of pICln, we have begun to identify the proteins that bind to it and the amino acid domains that mediate pICln protein^
protein interactions. Using affinity assays and immunoprecipitation we have identified three proteins in C6 glioma cells with
molecular masses of 17 kDa, 29 kDa and 72 kDa that bind selectively to pICln. Microsequencing revealed that p17 is the non-
muscle isoform of the alkali myosin light chain. pICln contains three acidic amino acid domains termed AD1, AD2 and AD3.
Mutation of AD1 and/or AD2 had no effect on p17, p29 and p72 binding. However, binding of p72 was lost when four acidic
amino acid residues were mutated in AD3, which is located at the carboxy terminus. A truncation peptide containing the last
29 amino acids of pICln was able to bind p72 normally. These results indicate that the carboxy terminus is necessary for p72^
pICln interaction. Based on these and other findings, we propose that pICln is a protein responsible for regulating the structure
and function of the cytoskeleton, and/or a protein involved in mediating interactions between components of intracellular
signal transduction pathways. 0167-4889 / 98 / $ ^ see front matter ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
An apparently ubiquitous response to swelling in
vertebrate cells is activation of an outwardly rectify-
ing anion current termed ICl; swell [1,2]. Molecular
identi¢cation of the protein(s) giving rise to ICl; swell
has been controversial and confusing [1^4]. Because
of its ability to induce in Xenopus oocytes an out-
wardly rectifying anion current that super¢cially re-
sembles ICl; swell, the protein pICln has been proposed
to be either the ICl; swell channel [5,6] or a channel
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regulator [7]. More recently, however, the role of
pICln in ICl; swell channel function has been called
into question (reviewed in Ref. [3]). The function of
pICln thus remains controversial and uncertain.
pICln most likely plays an important role in cell
function. The protein is ubiquitous in mammalian
cells and is also found in cells of lower vertebrates
such as Xenopus laevis [7] and zebra ¢sh [8]. pICln
structure is highly conserved across evolutionarily
divergent species, and the protein is expressed at
very high intracellular levels [7]. An understanding
of pICln function requires detailed cellular and mo-
lecular characterization of the protein and the mole-
cules that interact with it. In the present paper, we
have begun to characterize the proteins that bind to
pICln and the amino acid domains that mediate pICln
protein^protein interactions.
2. Materials and methods
2.1. Cell culture
Rat C6 glioma cells were cultured to near con£u-
ence in Eagle’s minimal essential medium (MEM;
Gibco, Gaithersburg, MD) with 10% fetal bovine
serum (FBS; Hyclone, Logan, UT) and penicillin/
streptomycin as described previously [9].
2.2. pICln protein a⁄nity assay
The cDNA coding for rat C6 glioma cell pICln was
cloned by standard homology screening using full-
length Madin^Darby canine kidney cell (MDCK)
pICln cDNA [5] as a probe. C6 glioma cell pICln is
94% homologous at the amino acid level to the
MDCK clone and identical to other pICln cDNA
clones isolated from rat kidney [10] and heart [7].
A fusion protein consisting of full-length pICln
fused to glutathione S-transferase (GST) was gener-
ated in BL21 E. coli using a commercially available
kit (Pharmacia Biotech, Piscataway, NJ) as described
previously [11]. GST^pICln protein was puri¢ed using
Glutathione Sepharose 4B. Protein yields were
judged by Coomassie blue staining. All binding
assays were performed with excess of fusion pro-
tein.
C6 cells were grown to 60^70% con£uence in 100-
mm diameter tissue culture plates. Cellular proteins
were labeled with 35S by incubating cells for 12 h in
7 ml of methionine- and cysteine-free MEM (Sigma,
St. Louis, MO) containing 10% FBS and 0.5 mCi of
[35S]methionine and [35S]cysteine (Expre35S35S; NEN
Life Sciences, Wilmington, DE). After incubation
with [35S]methionine and [35S]cysteine, cells were
rinsed twice with ice-cold phosphate-bu¡ered saline
(PBS; 2.7 mM KCl, 144 mM NaCl, 1.5 mM
KH2PO4, 8.1 mM Na2HPO4 ; pH 7.4). Individual
culture plates were then scraped into a microcentri-
fuge tube and incubated for 20 min at 4‡C with 0.5 ml
of lysis/binding bu¡er (50 mM KCl, 100 mM NaCl,
3 mM MgCl2, 0.5% Nonidet P-40, 1 mM EGTA,
1 mM DTT, 50 mM Tris, 1 mM phenylmethanesul-
fonyl £uoride (PMSF), 0.1 Wg/ml leupeptin; pH 7.4).
The lysed cells were centrifuged at 14 000 rpm for
10 min and the supernatant was removed and pre-
cleared of proteins that bind non-selectively to either
GST or Sepharose 4B. Pre-clearing was carried out
by incubating supernatants for 1 h with 50 Wl of GST
immobilized on Sepharose 4B. The Sepharose
4B-GST was removed by centrifugation, and the
supernatants were then incubated for 30 min with
20 Wl of Sepharose 4B alone followed by centrifuga-
tion.
Proteins that interact with pICln were isolated by
incubating 100 Wl of the pre-cleared supernatants
with 10 Wl of pICln^GST fusion protein immobilized
on Sepharose 4B. After 3 h, the resins were washed
four times with 1 ml of lysis/binding bu¡er, re-sus-
pended in 100 Wl of Laemmli bu¡er containing 2%
SDS and 50 mM L-mercaptoethanol and then boiled
for 3 min. Radioactive proteins released from the
resin were resolved by SDS^PAGE and autoradi-
ography.
2.3. Immunoprecipitation
Rabbit anti-pICln polyclonal antibodies were gen-
erated, and immunoprecipitation of 35S-labeled pro-
teins in C6 cell lysates was carried out as described
previously [11]. Immunoprecipitated proteins were
resolved by SDS^PAGE and autoradiography.
2.4. Protein microsequencing
Microsequencing was carried out on p17. The pro-
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tein was isolated and puri¢ed by scraping C6 cells
from 100 con£uent 10-cm diameter cell culture plates
into 0.5 ml of lysis/binding bu¡er and incubating on
ice for 20 min. Cellular debris was subsequently re-
moved by centrifugation at 14 000 rpm for 10 min at
4‡C. pICln and associated proteins were isolated by
co-immunoprecipitation with polyclonal pICln antise-
rum. Immunoprecipitated proteins were resolved in a
14% SDS^PAGE gel and blotted onto a PVDF
membrane. The membrane area containing p17 was
then isolated after visualization by amido black
staining. Automated microsequencing was performed
by Harvard Microchem (Harvard University Biolog-
ical Laboratories, Cambridge, MA).
3. Results
3.1. pICln binds selectively with 17 kDa, 29 kDa and
72 kDa proteins
As shown previously by Krapavinsky et al. [7],
pICln forms oligomeric complexes with several cyto-
solic proteins in MDCK and dog heart cells. In C6
glioma cell lysates, 35S-labeled proteins with appar-
ent molecular masses of 17^160 kDa were isolated
by GST^pICln a⁄nity assay. Binding of several of
these proteins to GST^pICln was observed inconsis-
tently. However, we were able to reproducibly detect
strong signals for three proteins with apparent mo-
lecular masses of 17 kDa, 29 kDa and 72 kDa (Fig.
1). p17 was detected infrequently as a doublet (Fig.
1).
Fig. 1. pICln forms oligomeric complexes with other cellular
proteins. Lanes 1 and 2: GST^pICln a⁄nity assay. 35S-Labeled
C6 glioma cell lysates were incubated with either immobilized
GST^pICln fusion protein or immobilized GST. Interacting pro-
teins were resolved by SDS^PAGE and autoradiography. Three
proteins with apparent molecular masses of 17 kDa, 29 kDa
and 72 kDa were found to bind consistently to GST^pICln (lane
2) and were not detected on immobilized GST alone (lane 1).
p17 was infrequently observed as a doublet. Five- and 10-fold
dilutions of the immobilized GST^pICln did not signi¢cantly af-
fect the recovery of p17, p29 and p72, demonstrating that a⁄n-
ity assays were performed with excess of target fusion protein
(data not shown). Lanes 3 and 4: 35S-labeled p17, p29 and p72
can also be isolated by co-immunoprecipitation with polyclonal
anti-pICln antibodies, suggesting that the interaction of these
proteins with pICln occurs in vivo.
Fig. 2. p17, p29 and p72 are competed o¡ GST^pICln by excess
recombinant pICln. 35S-Labeled C6 glioma cell lysates were in-
cubated with immobilized GST^pICln for 30 min. After wash-
ing, a⁄nity isolates were incubated for 12 h with bovine serum
albumin (BSA) or recombinant pICln added to a ¢nal concen-
tration of 0.2 mg/ml. In the presence of BSA, p17, p29 and p72
remained bound to GST^pICln (lane 1) and little or none of the
proteins was recovered from the supernatant (lane 3). p17, p29
and p72 appear in the supernatant (lane 4) when competed o¡
the immobilized fusion protein (lane 2) by free recombinant
pICln (lane 4).
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p17, p29 and p72 were also isolated by immuno-
precipitation of 35S-labeled C6 cells with anti-pICln
antiserum (Fig. 1). These ¢ndings demonstrate that
p17, p29 and p72 associate with pICln in vivo.
Because several of the pICln interacting proteins
were detected inconsistently, we focused all addition-
al studies on p17, p29 and p72. To test the speci¢city
of p17, p29 and p72 binding to pICln, competition
assays were performed. After washing, the a⁄nity
isolates were incubated overnight with BSA or re-
combinant pICln added to a ¢nal concentration of
0.2 mg/ml. As shown in Fig. 2, free pICln but not
BSA competed p17, p29 and p72 o¡ of the immobi-
lized GST^pICln, and caused the proteins to appear
in the supernatant.
Identi¢cation of the proteins that bind to pICln will
likely provide important clues to its function. Krapi-
vinsky et al. [12] recently identi¢ed p72 as a homolog
of yeast Skb1 (see Section 4). We were unable to
purify p29 for microsequencing. However, partial mi-
crosequencing of p17 generated the sequence
DQGTYEDYVEGLRVFDK, which is 100% homol-
ogous with amino acids 82^98 of the non-muscle iso-
form of human alkali myosin light chain [13]. The
apparent molecular mass of p17 is consistent with
the molecular mass of human alkali myosin light
chain predicted from the primary amino acid se-
quence.
3.2. Acidic domains AD1 and AD2 do not mediate
binding of p17, p29 and p72 to pICln
The amino acid sequence of rat pICln is shown in
Fig. 3. pICln contains two highly acidic domains,
AD1 and AD2, composed of multiple aspartate
Fig. 3. Amino acid sequence of C6 rat glioma cell pICln. Two
potential sites for initiation of translation at methionine resi-
dues 1 and 6 are indicated by arrows. Acidic domains AD1,
AD2 and AD3 are shown in bold. Glutamate and aspartate res-
idues mutated to alanine are indicated by asterisks.
Fig. 4. Acidic amino acid domains AD1 and AD2 do not mediate binding of p17, p29 and p72 to pICln. Lane 1: immobilized GST
control. Lane 2: p17, p29 and p72 binding to immobilized GST^pICln fusion protein. Lanes 3^5: mutation of four aspartate residues
to alanine (see Fig. 3) in either AD1 (lane 3), AD2 (lane 4), or both AD1 and AD2 (lane 5) had no e¡ect on p17, p29 and p72 bind-
ing to pICln. Lane 6: a 60-amino-acid truncation fragment spanning AD1 and AD2 (D100^A160) was not able to bind p17, p29 or
p72.
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and glutamate residues. An additional acidic domain,
AD3, is located at the carboxy terminus of the pro-
tein.
AD1 and AD2 have been proposed to be impor-
tant sites that mediate pICln protein^protein interac-
tions [7]. We tested this hypothesis by mutating four
aspartate residues to alanine in either AD1 or AD2,
or in both domains together (see Fig. 3) using stan-
dard PCR methods. As shown in Fig. 4, the binding
of p17, p29 and p72 was una¡ected by these muta-
tions. Consistent with this ¢nding, a 60-amino-acid
pICln truncation fragment (D100^A160) containing
both AD1 and AD2 was unable to bind these pro-
teins. These results demonstrate that AD1 and AD2
are not involved in the binding of p17, p29 and p72
to pICln.
3.3. p72 binds to acidic domain AD3
In an e¡ort to identify other sites of pICln protein^
protein interaction, we generated a series of trunca-
tion constructs. We were not able to detect consistent
alterations in p17 and p29 binding with any of these
proteins (data not shown). This suggests that second-
ary protein structure may be necessary for the in-
teraction of these proteins with pICln. However, as
shown in Fig. 5, p72 binding was lost or dramatically
reduced in truncation constructs lacking AD3. p72
binding was not detected with the M1^F234 con-
struct (lane 2, Fig. 5B). A very faint band was de-
tected with the construct spanning A160^F234 (lane
3, Fig. 5B). This band ran somewhat higher than p72
and it is not clear whether it represents a small
amount of residual p72 binding or non-speci¢c bind-
ing of some other protein. A construct spanning the
last 29 amino acids (D213^H241) of the protein,
which contains AD3, was su⁄cient to retain p72
binding (lane 5, Fig. 5B). Furthermore, p72 binding
to full-length pICln was lost when the four glutamate
and aspartate residues in AD3 were mutated to ala-
nine (Fig. 5B, lane 6). p17 and p29 binding were not
a¡ected by mutation of AD3 (data not shown). Tak-
Fig. 5. Acidic amino acid domain AD3 (see Fig. 3) mediates p72 binding to pICln. (A) Diagram showing pICln truncation fragments
and AD3 mutant. (B) Full-length (WT) pICln and pICln truncation fragments containing AD3 (A160^H241 and D213^H241) bind p72.
p72 binding is not detected on truncation fragments lacking AD3 (M1^F234 and A160^F234). To further assess the role of AD3 in
p72 binding, three aspartate residues and one glutamate residue in this region (right side in A; see also Fig. 3) were mutated to ala-
nine (AD3 mutant). These mutations disrupted p72 binding. The results shown were obtained from a single gel. Equal amounts of
protein were added to each lane.
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en together, these results suggest strongly that p72
binding is mediated by AD3.
4. Discussion
4.1. Interaction of pICln with cytoskeletal proteins
Krapivinsky et al. [7] demonstrated that pICln
forms tight and apparently speci¢c complexes with
a number of other cytosolic proteins (see also Ref.
[12]). Two of the proteins they described have appar-
ent molecular masses of 29 kDa and 72 kDa, which
is consistent with our ¢ndings (Figs. 1 and 2).
p17 was not identi¢ed by Krapivinsky et al. [7] in
their initial binding studies, possibly because the
acrylamide concentrations they used were too low
to resolve this protein. More recently, they detected
a 17 kDa protein by co-immunoprecipitation with
pICln [12]. We identi¢ed p17 by microsequencing as
the non-muscle isoform of the alkali myosin light
chain [13]. The function of the non-muscle isoform
of myosin light chain is uncertain. However, in
muscle cells, myosin light chain is thought to play
an important role in regulating muscle contraction
[14].
Human p72 was cloned recently using microse-
quencing and expressed sequence tag (EST) database
screening [12]. The open reading frame of p72 pre-
dicts a 637-amino-acid protein with a molecular mass
of 72.6 kDa. p72 has no homology with other cloned
mammalian proteins. However, it shows 52% amino
acid homology with the yeast Skb1 protein. Skb1
interacts with Shk1, which is a homolog of mamma-
lian p21-activated protein kinases (PAKs) [15]. These
kinases are activated by the GTP-binding proteins
Rho, Rac and Cdc42, and may play an important
role in controlling cytoskeletal architecture, cell mo-
tility, the cell cycle and stress responses [15].
Krapivinsky et al. [7] also proposed that actin
binds in an apparently selective fashion to pICln.
Schwartz et al. [16] have shown actin^pICln interac-
tion using a yeast two-hybrid assay. In our hands,
however, we did not consistently detect actin^pICln
interactions. Furthermore, when we isolated actin by
either a⁄nity assay or immunoprecipitation, we were
unable to demonstrate that it interacted selectively
with pICln. Actin binding was detected with immobi-
lized GST alone and by immunoprecipitation using
pre-immune serum (data not shown).
4.2. Role of acidic domains in mediating pICln
protein^protein interactions
pICln protein^protein interactions occur in vitro
after the protein is denatured by boiling or SDS
[7]. As noted by Krapivinsky et al. [7], such behavior
is reminiscent of protein^protein interactions that are
mediated by primary amino acid sequences such as
SH2 and SH3 domains. These ¢ndings led to the
hypothesis that clusters of acidic amino acid residues
(i.e., AD1 and AD2; see Fig. 3) may be important
for protein binding in pICln. As shown in Fig. 4,
mutation of aspartate residues to alanine in AD1
and/or AD2 had no e¡ect on the interaction of
pICln with p17, p29, and p72. A 60-amino-acid
pICln truncation fragment containing both AD1 and
AD2 was not capable of binding any of the three
proteins (Fig. 4). The data shown in Fig. 4 suggest
that these acidic amino acid domains do not mediate
p17, p29 and p72 binding.
pICln interacts with a constitutively active protein
kinase that is capable of phosphorylating it and a
variety of other proteins [11]. Kinase binding is sen-
sitive to salt concentration, suggesting that it is medi-
ated by charged amino acid residues. Consistent with
this observation, we demonstrated that the kinase
binds only to pICln fragments containing AD1 and
AD2, and that a 56-amino-acid fragment spanning
both these domains is su⁄cient for kinase binding
[11]. Thus, AD1 and AD2 may be important for
mediating certain pICln protein^protein interactions.
Importantly, the lack of binding of p29 and p72 to
AD1 and AD2 indicates that these proteins are not
the pICln-associated kinase.
In addition to AD1 and AD2, we identi¢ed a third
acidic domain (AD3) spanning E235^H241, which is
located on the extreme carboxy terminus of pICln
(Fig. 3). AD3 is essential for p72 binding. As shown
in Fig. 5, deletion of the seven amino acids compris-
ing AD3, or mutation of the four aspartate and glu-
tamate residues in AD3 to alanine, prevents p72
binding. Furthermore, a truncation construct consist-
ing of the last 29 amino acids in the carboxy termi-
nus of pICln is su⁄cient for p72 binding. Our con-
clusions are supported by recent studies of
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Krapivinsky et al. [12]. These investigators demon-
strated that p72 binding was lost from a pICln trun-
cation construct lacking the last 37 amino acids of
the carboxy terminus.
Carboxy terminal acidic amino acid domains play
important roles in mediating some types of protein^
protein interactions. For example, the acidic carboxy
terminus of tubulin is required for binding of certain
microtubule-associated proteins [17]. Mutation of
acidic amino acids comprising the carboxy terminus
of furin alters tra⁄cking of this protein between the
trans-Golgi network and the plasma membrane [18].
The acidic carboxy terminus of nuclear Ran/TC4, a
member of the Ras superfamily of GTPases, is im-
portant for stabilizing GDP binding and for media-
ting the interaction of Ran with regulatory proteins
[19].
4.3. Possible functions of pICln
When overexpressed in Xenopus oocytes, pICln in-
duces an outwardly rectifying anion current that
super¢cially resembles a ubiquitous swelling-acti-
vated anion current termed ICl; swell [1^4]. Initially,
pICln was proposed to be the channel responsible
for ICl; swell [5,6]. However, a variety of new ¢ndings
seriously challenge this hypothesis. Voets et al. [20]
have shown that the pICln-induced current has char-
acteristics distinct from those of the endogenous
ICl; swell activated by swelling of oocytes [21,22].
Buyse et al. [23] have shown that (1) expression of
an unrelated protein, ClC-6, induces the same cur-
rent as that induced by expression of pICln, and (2)
the pICln-associated current is observed without
cRNA injection in about 5^6% of oocytes [5]. Muta-
genesis studies [5] that provided compelling support
for the hypothesis that pICln is a channel-forming
protein have not been reproduced [24]. Furthermore,
reconstitution of puri¢ed recombinant pICln in bi-
layers does not generate anion channel activity [25],
and it has not been possible to unequivocally detect
pICln in cell membranes (reviewed in Ref. [3]). Based
on these ¢ndings, it has been proposed that heterol-
ogous expression of pICln in oocytes activates an en-
dogenous anion current distinct from ICl; swell [20,23].
The anion current thought to be induced by expres-
sion of mutant pICln [5] has also been proposed to
arise from an endogenous oocyte anion channel [24].
Krapivinsky et al. [7] proposed that pICln is an
ICl; swell regulator because of its biochemical proper-
ties and the fact that it is localized predominantly to
the cytoplasm. They suggested that expression of the
protein in oocytes turned on an endogenous ICl; swell
channel. Given the fact that the current induced in
oocytes by pICln is distinct from ICl; swell, and that it
can also be induced by the unrelated protein ClC-6
[20,23], it seems unlikely that pICln is a direct regu-
lator of the ICl; swell channel. However, it remains
possible that pICln indirectly a¡ects ICl; swell activity.
Krapivinsky et al. [7] demonstrated that injection of
anti-pICln antibodies into oocytes inhibited swelling-
induced activation of ICl; swell. Transfection with pICln
antisense RNA slows ICl; swell activation in ¢broblasts
[6] and tsA201 [26] cells. In tsA201 cells, overexpres-
sion of pICln increases the rate of ICl; swell activation
[26].
If pICln is not the ICl; swell channel or channel reg-
ulator per se, what is its function? One possibility is
that pICln is a protein involved in regulating cytoskel-
etal function and structure as we have suggested
previously [3]. This hypothesis is consistent with the
observations that pICln interacts with the non-muscle
isoform of the alkali myosin light chain and possibly
actin [7,16], and that p72 may be a mammalian ho-
molog of a yeast protein that binds PAKs [12]. The
binding of p72 to the acidic carboxy terminus is also
suggestive of role for pICln in cytoskeletal function.
As noted above, carboxy terminal acidic amino acid
domains play important roles in microtubule struc-
ture [17] and intracellular protein tra⁄cking [18].
If pICln is a cytoskeletal regulatory protein, it
could explain how altering its function or expression
levels alters ICl; swell activation [6,7,26]. Swelling-in-
duced activation of ICl; swell is modi¢ed by cytoskele-
tal disrupting agents [27,28]. Disruption of pICln may
disrupt the cytoskeleton, which in turn could alter
the activity of the ICl; swell and other channels.
Another, not necessarily mutually exclusive hy-
pothesis, is that pICln functions as a ‘sca¡olding pro-
tein’ for bringing together and possibly regulating
components of signal transduction pathways. Such
a sca¡olding function has been ascribed to so-called
14-3-3 proteins [29,30]. It is interesting to note that
14-3-3 proteins have biochemical characteristics not
unlike those of pICln. Both proteins are small (27^30
kDa), highly acidic, abundant, ubiquitous, and have
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highly conserved structures. In addition, both pro-
teins self-associate [30,31] and are distributed
throughout the cytoplasm. 14-3-3 proteins bind to
and possibly regulate a variety of protein kinases,
and they have been suggested to coordinate signal
transduction molecules that control diverse processes
such as the cell cycle, the structure of the actin cy-
toskeleton, neurosecretion, development, and neuro-
plasticity [29,30]. The hypothesis that pICln has a
function analogous to that of 14-3-3 proteins is con-
sistent with the observation that a constitutively ac-
tive protein kinase interacts speci¢cally with pICln
[11], and that p72 may be a mammalian homolog
of a yeast protein that binds p21-activated protein
kinases [12]. If the sca¡olding hypothesis is correct,
alterations in pICln activity and expression could in-
directly disrupt a large number of physiological pro-
cesses, including ion channel regulation.
Whatever the function of pICln is, it is almost cer-
tainly important to cellular physiology. Continued
identi¢cation of the proteins that bind to and inter-
act with pICln, as well as characterization of amino
acid domains that mediate protein^protein interac-
tions, will provide important clues and insights into
its physiological role.
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